日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

UGT1A1*28 多态性与接受 sacituzumab govitecan 治疗的乳腺癌患者的毒性和疾病进展风险相关

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.70096
Wong, Megan H; Jones, Veronica C; Yu, Wai; Bosserman, Linda D; Lavasani, Sayeh M; Patel, Niki; Sedrak, Mina S; Stewart, Daphne B; Waisman, James R; Yuan, Yuan; Mortimer, Joanne E
肿瘤
毒理研究
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer

一项针对HER2阳性原发性乳腺癌患者的新辅助nab-紫杉醇、曲妥珠单抗和帕妥珠单抗的II期前瞻性开放标签研究

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.34589
Lavasani, Sayeh M; Somlo, George; Yost, Susan E; Frankel, Paul H; Ruel, Christopher; Cui, Yujie; Murga, Mireya; Tang, Aileen; Martinez, Norma; Kruper, Laura; Tumyan, Lusine; Schmolze, Daniel; Yeon, Christina; Yuan, Yuan; Waisman, James R; Mortimer, Joanne
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏